Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Marinus Pharmaceuticals Inc.
Headquarters: Radnor, PA, United States of America
Website: http://www.marinuspharma.com...
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Anders Edvell, MD, PhD
Number Of Employees: 165
Enterprise Value: $544,295,000
PE Ratio: -0.22
Exchange/Ticker 1: NASDAQ:MRNS
Exchange/Ticker 2: N/A
Latest Market Cap: $29,628,000
BioCentury | Sep 5, 2024
Management Tracks
Pfizer names Elif Aral president of MERA
Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more
BioCentury | Apr 16, 2024
Product Development
Clinical report: Proof of concept for Allay’s implantable analgesic, with Singapore tech
Plus: Intra-Cellular’s Caplyta scores a win in major depressive disorder; and readouts for Marinus, Ultragenyx weigh on shares
BioCentury | Jan 23, 2024
Management Tracks
Siga names Diem Nguyen CEO
Plus: Fish & Richardson names Sawert as principal and updates from ImmunoBrain and DiaMedica
BioCentury | Jun 29, 2023
Management Tracks
Dallas replaces Cunningham as CEO of Rivus
Plus: Stephen Uden named CEO at Rallybio, and updates from Alloy, TScan and more
BioCentury | May 26, 2023
Data Byte
CHMP seeks to pull Adakveo’s conditional approval; drug has full FDA approval
EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroya
BioCentury | Jan 19, 2023
Politics, Policy & Law
Hopes, Fears for Orphan Drug Act
Passed 40 years ago, it may be time for ODA 2.0
BioCentury | Nov 18, 2022
Regulation
Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes
Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
BioCentury | Nov 9, 2022
Regulation
Nov. 8 Quick Takes: FDA request could extend review of BioMarin’s hemophilia therapy
Plus Sanofi’s latest AI deal taps Insilico and updates from Kronos, Marinus and more
BioCentury | Jul 15, 2022
Politics, Policy & Law
July 14 Quick Takes: Illumina, BGI end U.S. legal battle
Plus FDA delays BeiGene’s BLA, Manifold raises $40M and updates from Theravance, Marinus, and more
BioCentury | Mar 22, 2022
Deals
March 21 Quick Takes: Pear looks East with SoftBank deal
Plus FDA approves Marinus’ anticonvulsive and updates from Bavarian Nordic, Nuance, Provention, Qu and more
Items per page:
1 - 10 of 58